Table 2.

Motesanib treatment–related adverse events occurring in ≥10% of patients and related adverse events of interest

Related adverse events, no. of patients (%)Arm A (n = 23)Arm B (n = 16)Arm C (n = 6)
All gradesGrade 3Grade 4All gradesGrade 3Grade 4All gradesGrade 3Grade 4
Patients with any related adverse event21 (91)15 (65)3 (13)15 (94)8 (50)0 (0)6 (100)2 (33)2 (33)
Related adverse events occurring in ≥10% of patients
    Fatigue12 (52)6 (26)0 (0)11 (69)3 (19)0 (0)4 (67)1 (17)0 (0)
    Diarrhea12 (52)1 (4)0 (0)7 (44)1 (6)0 (0)5 (83)0 (0)0 (0)
    Hypertension10 (43)6 (26)0 (0)6 (38)4 (25)0 (0)1 (17)0 (0)0 (0)
    Anorexia5 (22)2 (9)0 (0)6 (38)2 (13)0 (0)1 (17)0 (0)0 (0)
    Nausea4 (17)0 (0)0 (0)4 (25)0 (0)0 (0)2 (33)0 (0)0 (0)
    Arthralgia3 (13)1 (4)0 (0)2 (13)2 (13)0 (0)2 (33)0 (0)0 (0)
    Headache4 (17)0 (0)0 (0)2 (13)1 (6)0 (0)1 (17)1 (17)0 (0)
    Weight loss4 (17)0 (0)0 (0)1 (6)0 (0)0 (0)2 (33)0 (0)0 (0)
    Dyspnea4 (17)1 (4)0 (0)0 (0)0 (0)0 (0)2 (33)0 (0)0 (0)
    Hypomagnesemia4 (17)0 (0)0 (0)2 (13)0 (0)0 (0)0 (0)0 (0)0 (0)
    Vomiting1 (4)0 (0)0 (0)4 (25)1 (6)0 (0)1 (17)0 (0)0 (0)
    Pruritus1 (4)0 (0)0 (0)3 (19)0 (0)0 (0)1 (17)0 (0)0 (0)
    Myalgia3 (13)0 (0)0 (0)2 (13)0 (0)0 (0)0 (0)0 (0)0 (0)
    Pain in extremity1 (4)0 (0)0 (0)0 (0)0 (0)0 (0)4 (67)0 (0)0 (0)
    Dizziness3 (13)0 (0)0 (0)2 (13)0 (0)0 (0)0 (0)0 (0)0 (0)
Patients with related adverse events of interest
    Pulmonary embolism4 (17)*1 (4)3 (13)0 (0)0 (0)0 (0)2 (33)*0 (0)2 (33)
    Cholecystitis1 (4)1 (4)0 (0)2 (13)2 (13)0 (0)0 (0)0 (0)0 (0)
    Deep vein thrombosis1 (4)1 (4)0 (0)0 (0)0 (0)0 (0)1 (17)1 (17)0 (0)
    Thrombosis1 (4)*0 (0)0 (0)0 (0)0 (0)0 (0)1 (17)*1 (17)0 (0)
    Hemorrhage3 (13)1 (4)0 (0)3 (19)0 (0)0 (0)3 (50)0 (0)0 (0)
        Gastrointestinal1 (4)1 (4)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)
        Other2 (9)0 (0)0 (0)3 (19)0 (0)0 (0)3 (50)§0 (0)0 (0)
    Cardiac disorders2 (9)0 (0)0 (0)1 (6)0 (0)0 (0)0 (0)0 (0)0 (0)
  • *One patient experienced pulmonary embolism and thrombosis.

  • Urinary tract hemorrhage and hemoptysis.

  • Epistaxis (n = 2) and hemoptysis.

  • §Epistaxis (n = 2) and hematuria.

  • Atrial fibrillation (n = 1) and conduction disorder (n = 1).

  • Atrial fibrillation (n = 1) and sinus tachycardia (n = 1).